JP2025508389A - 慢性リンパ性白血病のｂ細胞受容体を標的とする抗体及びその使用 - Google Patents

慢性リンパ性白血病のｂ細胞受容体を標的とする抗体及びその使用 Download PDF

Info

Publication number
JP2025508389A
JP2025508389A JP2024547778A JP2024547778A JP2025508389A JP 2025508389 A JP2025508389 A JP 2025508389A JP 2024547778 A JP2024547778 A JP 2024547778A JP 2024547778 A JP2024547778 A JP 2024547778A JP 2025508389 A JP2025508389 A JP 2025508389A
Authority
JP
Japan
Prior art keywords
antibody
seq
iglv3
antibodies
cll
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508389A5 (https=
Inventor
デューレン－フォン ミンデン マークス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinabiosolution GmbH
Original Assignee
Sinabiosolution GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP22156205.1A external-priority patent/EP4227321A1/en
Application filed by Sinabiosolution GmbH filed Critical Sinabiosolution GmbH
Publication of JP2025508389A publication Critical patent/JP2025508389A/ja
Publication of JP2025508389A5 publication Critical patent/JP2025508389A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024547778A 2022-02-10 2023-02-09 慢性リンパ性白血病のｂ細胞受容体を標的とする抗体及びその使用 Pending JP2025508389A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22156205.1A EP4227321A1 (en) 2022-02-10 2022-02-10 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll
EP22156205.1 2022-02-10
EP22156209.3 2022-02-10
EP22156209 2022-02-10
PCT/EP2023/053160 WO2023152204A1 (en) 2022-02-10 2023-02-09 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll

Publications (2)

Publication Number Publication Date
JP2025508389A true JP2025508389A (ja) 2025-03-26
JP2025508389A5 JP2025508389A5 (https=) 2026-02-18

Family

ID=85410412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547778A Pending JP2025508389A (ja) 2022-02-10 2023-02-09 慢性リンパ性白血病のｂ細胞受容体を標的とする抗体及びその使用

Country Status (7)

Country Link
US (1) US20250145706A1 (https=)
EP (1) EP4476264A1 (https=)
JP (1) JP2025508389A (https=)
KR (1) KR20250004625A (https=)
CN (1) CN118984838A (https=)
CA (1) CA3243736A1 (https=)
WO (1) WO2023152204A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3262006A1 (en) * 2022-07-25 2024-02-01 Sinabiosolution Gmbh Humanized chimeric antigen receptors targeting the B-lymphocyte receptor in chronic lymphocytic leukemia and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ATE375365T1 (de) 1998-04-02 2007-10-15 Genentech Inc Antikörper varianten und fragmente davon
EP3424527A1 (de) 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostisches verfahren
WO2020127827A1 (de) * 2018-12-20 2020-06-25 Ava Lifescience Gmbh Verfahren zur selektion biologischer bindemoleküle
CA3148214A1 (en) * 2019-05-02 2020-11-05 Ava Lifescience Gmbh Antigent binding domains and uses therefor

Also Published As

Publication number Publication date
US20250145706A1 (en) 2025-05-08
WO2023152204A9 (en) 2023-11-30
CN118984838A (zh) 2024-11-19
CA3243736A1 (en) 2023-08-17
WO2023152204A1 (en) 2023-08-17
WO2023152204A8 (en) 2024-01-04
KR20250004625A (ko) 2025-01-08
EP4476264A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
US12121579B2 (en) Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
ES2768784T3 (es) Anticuerpos anti-CEACAM6 y usos de los mismos
CN112513080B (zh) Vista抗原结合分子
ES2791249T3 (es) Agentes de enlace CD123 y sus utilizaciones
US20140322220A1 (en) Anti-FGFR2 Antibodies and Uses Thereof
JP2020536109A (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
TR201910145T4 (tr) Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik.
WO2015076425A1 (ja) 新規モノクローナル抗体
CN106687477A (zh) 药物、用途以及方法
KR20220151195A (ko) 항-cd36 항체 및 암을 치료하기 위한 이의 용도
US20230331842A1 (en) Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
US20250145706A1 (en) Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
WO2024062019A1 (en) Anti-ccr8 antibodies and uses thereof
CA3216131A1 (en) Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4)
US20250206836A1 (en) Anti-cd36 antibodies and their use to treat cancer
WO2025191147A1 (en) Anti-ccr8 antibodies and uses thereof
KR20240051162A (ko) 부작용이 감소된 항-cecam6 항체
CA2997130C (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
HK40112156A (zh) 药物、用途以及方法
EP4229094A1 (en) Multispecific binding compounds that bind to pd-l1
HK1246312B (zh) 抗ceacam6抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260209